heart failure glp-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms Cardiovascular disease continuum-GLP-1 action. Adapted
Description
& Heneka, M
Those in the higher dose group were also significantly more likely to reach weight reductions of up to 20% of their waist circumference (a clinically meaningful measure of cardiometabolic risk) and improve their HbA1C (a measure of blood sugar control) compared with the other two groups
Your GLP-1 dose might need an increase
For those who cannot tolerate whey, plant-based protein blends combining pea, rice, and hemp proteins provide comparable amino acid profiles
A Note on Ozempic Face : Rapid fat loss can change facial appearance
